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Abstract
There is now scientific evidence of genetically driven skin barrier anomalies in atopic
patients. These barrier anomalies facilitate sustained antigen ingress through the defective
barrier, which can bring about a Th2-dominant response. It enhances the transepidermal
water loss, resulting in dry skin and leading to the release of pre-formed pro-inflammatory
cytokines and to a cascade of events ending up in inflammation.
There is scientific evidence indicating that skin barrier dysfunction plays a prominent role in
the development and perpetuation of atopic dermatitis (AD), the “outside-to-inside” view of
AD pathogenesis. Moisturizers have a pivotal role in improving and maintaining the skin
barrier function and in reducing skin susceptibility to irritants. These emollients are a
standard of care, the mainstay of AD therapy, and useful for both prevention and maintenance
therapy.
Regular use of emollients has a short- and long-term steroid-sparing effect in mild-tomoderate AD. They should be recommended in adequate amounts and used liberally and
frequently in atopic patients. Recently, “Barrier-repair therapeutics” has entered the market,
generally as devices, requiring prescriptions (510k-cleared moisturizers). Although this new
class of moisturizers has shown excellent performance, efficacy, and safety, we could raise
questions about their superiority over a well-crafted traditional, petrolatum-based OTC
emollient, as we have been unable to find any scientific evidence to support this claim. In
addition, there is currently no definition for “barrier-repair products,” raising the additional
question of whether such presently available products could justify such a category.
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The "outside-to-inside" view of atopic dermatitis and its therapeutic implications
Until recently, it was thought that the pathogenic mechanism of atopic dermatitis (AD) was
initiated by immune dysfunction leading to Th1/Th2 cell dysregulation, IgE production, mast
cell hyperactivity, and dendritic cell signaling. Although both defective epidermal
permeability that causes dry skin and leads to a predisposition to secondary infection are
well-recognized features of AD, these conditions have been widely assumed to reflect
downstream consequences of a primary immunologic abnormality (the historical "inside-tooutside" view of AD pathogenesis). Accumulating evidence, however, now suggests that a
primary defect in the stratum corneum may play a key role not only in initiating but also in
perpetuating AD. This dysfunction of the barrier leads to the release of pre-formed proinflammatory cytokines and sets into motion a cascade of events that provoke and sustain
disease activity (the "outside-to-inside" view of AD pathogenesis).
Two main mechanisms account for the outside-to-inside direction of events, that is to say,
from the impaired barrier to the development of the inflammation. One is the release of a
cytokine cascade that up-regulates lipid synthesis, lamellar body secretion, and epidermal
proliferation aimed at the restoration of the barrier function and the initiation of
inflammation. The other is the penetration of irritants, allergens, haptens, superantigens, and
bacterial toxins.
Awareness of the primary role of the stratum corneum in the pathogenesis of AD, as well as
in other inflammatory diseases, has opened up new therapeutic options and a new therapeutic
concept: to treat not only the inflammation but also to restore the barrier. The historical
origins of this concept derive from the numerous, innovative works of Elias and co-workers,
which have been well presented in a 2001 paper with the catchy title, "Does the tail wag the
dog?" 1 A further step in this direction was the development of a new pharmacologic
approach aimed at barrier repair. It involves the delivery of balanced proportions of stratum
corneum-specific lipids to assist in correcting this epidermal barrier dysfunction.
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In a state of physiologic balance, the approximate proportions of the lipid component are
predominantly composed of 50% ceramides, 25% cholesterol, and 10-20% free fatty acids. In
AD, there is a decrease in all three key lipids, especially ceramides, which are found in both
affected and non-affected skin. A lipid imbalance and inadequate amounts of ceramides
contribute to defective formation of the corneocyte lipid envelope and lipid mortar, which
correlate with increased transepidermal water loss and enhanced barrier permeability 2.
These scientific findings have led to a second look at the use of moisturizers.
There has been a shift from traditional moisturizers towards ceramide-dominant physiological
lipid-base barrier-repair topical emulsions. According to several reports 2 , these formulations
focus on physiologic lipid replacement therapy, particularly ceramides, to restore the normal
balance of the epidermal barrier. Compared with other emollients that form a more superficial
occlusive barrier (e.g., petrolatum), ceramide-dominant moisturizers are thought to permeate
the stratum corneum and to be synthesized in the keratinocytes, processed in the lamellar
bodies, and secreted back into the stratum corneum, where they become a part of the dermal
matrix.
In an extensive review by Elias 3, the developer of barrier-repair therapeutics, he states:
“Typical emollient moisturizers, even if they provide some temporary relief through
moisturization, actually degrade, rather than improve, barrier function, and by providing
partial relief, they actually delay barrier repair." This, he claims, is in contrast to the use of
corrective barrier repair creams that contain "sufficient quantities of all three key lipids that
mediate barrier function (i.e., cholesterol, free fatty acids, and ceramides)…"
510(k)-cleared prescription moisturizers
These barrier-repair products to which Elias is referring are technically different from
traditional over-the-counter (OTC) nonprescription moisturizers, because the Food and Drug
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Administration (FDA) has approved them as 510(k) devices. The 510(k) device approval
process was originally developed to ensure the safety of equipment with an on/off switch. A
device that reaches market via the 510(k) process is not considered to be "approved" by the
FDA, but it can still be marketed and sold in the United States. Such products are generally
referred to as "cleared" or "510(k)-cleared" devices, where the focus is on safety as opposed
to efficacy. Although creams are not traditionally thought of as "devices," these topical
agents have received 510(k) approval, because they induce a physical change in the skin,
specifically, an increase in skin hydration resulting from a decrease in the transepidermal
water loss (it is important to note that OTC moisturizers should have exactly the same effect,
but they have not been registered as devices). Various formulations that produce barrier
repair by different mechanisms currently have 510(k) approval as prescription drugs.
Ceramide-dominant physiological lipid-base barrier-repair products.
"EpiCeram® Skin Barrier Emulsion" can be considered as the prototype of a ceramidedominant physiological lipid-base barrier-repair product. According to Elias’ description, it is
made up of ceramides, free fatty acids, and cholesterol in what is labeled “optimized
proportions (i.e., a 3:1:1 molar ratio)” The product obtained marketing clearance from the
FDA in April 2006. What is interesting about this moisturizer is that it had originally been an
OTC product called Triceram® and was subsequently designated as a prescription product
called Epiceram®, with no known changes having been made in its chemical structure.
Chamlin and colleagues 4 published a letter of correspondence entitled “The initial promising
results of a phase 1 trial of a ceramide-dominant, barrier-repair moisturizer in childhood
atopic dermatitis.” The final results of this trial then appeared as an original report 5. This
modest study was performed on 24 children who continued their prior therapy for stubbornto-recalcitrant AD with the only change, being the substitution of their usual moisturizer with
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the barrier-repair emollient. These authors reported impressive results. The severity scoring
of AD (SCORAD) values improved significantly in 22 of the children by 3 weeks and in all
24 of them by 21 weeks. Transepidermal water loss levels (TEWL), which were elevated
over involved and uninvolved areas at entry, decreased in parallel with SCORAD scores and
continued to decline even after the SCORAD scores plateaued. In conclusion: “A ceramidedominant, barrier-repair emollient represents a safe, useful adjunct to the treatment of
childhood AD”.
In a five-center, investigator-blinded, randomized trial 6, EpiCeram® was compared to a midpotent steroid (Cutivate® (fluticasone ) ) cream in 121 moderate-to-severe AD patients, aged
six months to 18 years. EpiCeram® reduced clinical disease severity, decreased pruritus, and
improved sleeping habits at both 14 and 28 days after initiation of therapy. Although the
fluticasone-treated group showed significantly greater improvement at 14 days, SCORAD,
pruritus and sleeping habit scores for EpiCeram did not differ significantly from the
fluticasone-treated group by 28 days. The conclusion of the authors was: " the ceramidedominant, physiological-lipid based formulation could represent an effective stand-alone or
ancillary therapy for many pediatric patients with AD". What is missing is a study with a
control group of age-matched pediatric AD patients who were treated solely with OTC
moisturizers.
In another 5-center, open-label, interventional study 7, a ceramide-dominant, physiologic
lipid-based emulsion (EpiCeram ®) was evaluated for three weeks either as monotherapy or
in combination with another AD treatment in 207 patients with mild-to-moderate AD.
Overall, approximately one-half of the subjects achieved success with investigator global
assessment (clear or almost clear investigator global assessment scores) after three weeks of
treatment. A large proportion of subjects (75%) and investigators (for 77% of the subjects)
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reported satisfaction after three weeks of treatment. Unique to this study was the direct
involvement of subjects in deciding whether to use an additional treatment in combination
with the tested moisturizer. The majority of subjects (71%) chose not to add the prescribed
medication to the ceramide-dominant, physiologic lipid-based product during the three-week
study period. In conclusion: "…the product was shown to be an effective agent, with or
without additional topical therapy, to provide good clinical efficacy and high levels of
investigator and patient satisfaction for many patients with mild-to-moderate AD.”
The 3-month- to 16-year-old subjects who had been evaluated in the study underwent a
subgroup analysis 8 and the results indicated : "a large percentage of subjects (71%) reported
satisfaction with clinical results". Again, there was no comparison of the results with a
matched control group treated with OTC moisturizers.
Subsequent to the claims that EpiCeram® is in a class of its own as a stand-alone moisturizer,
being superior, came a paper 9 comparing EpiCeram® with another newly developed
hyaluronic acid-based foam among 30 subjects with mild dermatitis and 30 subjects with
moderate dermatitis. It was an investigator-blinded and split-body studies in which the
patients with moderate dermatitis were asked to use additionally a triamcinolone acetonide
0.1% cream. The authors concluded: "both formulations achieved statistically significant
improvement in all clinical signs and symptoms of AD by week 4; however, the hyaluronic
acid foam achieved statistically significant improvement in overall dermatitis severity by
week 2, whereas the ceramide-containing emulsion cream did not. Could this indicate that
there might be a chink in the armor??
For the record, there are at least 3 other products approved as 510(k) medical device creams
that have become available over the past several years and cleared by the FDA for the
treatment of AD. One of those 3 products is Atopiclair®, a nonsteroidal multicomponent
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product in which some key ingredients are mixed together with oil in water emulsion. Its
beneficial effects have been proven in several impressive studies. We found four such
multicenter, randomized, vehicle-controlled clinical studies that evaluated it. The first 10
comprised 218 adults with mild-to-moderate AD, who administered the test cream or vehicle
cream 3 times per day to affected areas and those areas prone to be affected. The primary
endpoint of the study was the score of the Eczema Area and Severity Index (EASI) at day 22.
The results showed that the cream was statistically more effective than vehicle in all
outcomes. As could be expected, the authors’ conclusions were: “…the cream is rapidly
effective and safe as a non-steroidal monotherapy in mild to moderate AD, and it may be
useful as a topical steroid sparing agent”.
The third of the four multicenter studies that we found 12 was a randomized, double-blind,
vehicle-controlled trial comprised of 142 patients aged 6 months to 12 years, whose treatment
consisted of applying either the test substance or the vehicle 3 times per day. The primary
endpoint for efficacy was the Investigator's Global Assessment (IGA) score for AD at day 22.
The secondary endpoints were patient/caregiver's assessment of pruritus, onset, duration of
itch relief, the EASI score, and the need for rescue medication in the event of an AD flare.
The test substance (Atopiclair®) was found to be significantly more effective (P<. 0001) than
the vehicle cream for the primary endpoint and for all the secondary endpoints in this cohort
of infants and children.
The fourth multicenter double-blind, randomized, vehicle-controlled study on 60 pediatric
patients13 also showed a significant difference between the tested product (Atopiclair®) and
the vehicle. This study consisted of a treatment period of 43 days. The test substance showed
80% improvement in the IGA score at day 22, compared with a score of 26.3% for the
vehicle. This statistical significance was sustained until the end of the study. The authors’
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conclusions were that the product “may be considered as one of the available regimens
effective in the treatment of mild-to-moderate AD in children and adolescents". An OTC
moisturizer control group was again conspicuously missing.
The second prescription device
cream, Mimyx®, contains a unique lamellar matrix of pharmaceutical emollient substances,
including palmitoylethanolamine (PEA). PEA is a cannabinoid agonist that has antiinflammatory, antipruritic features and the capacity to inhibit mast cell activation. We are
aware of at least one very large, multinational, multicenter, non-controlled prospective study
14

in which data on the effect of Mimyx® on 2456 patients from 525 centers were analyzed.

The study showed substantial relief of objective and subjective manifestations of AD. The
intensities of symptoms were reduced (with a combined score reduction of 58% in the entire
population), previously used topical corticosteroids were discontinued by 56% of all patients,
and the average weekly application rate decreased by 62%.
The third prescription topical cream is the lipid-rich Eletone® emulsion. An investigatorblinded bilateral study 15 compared Eletone® emulsion with pimecrolimus cream 1% among
20 patients with mild to moderate AD. The participants applied pimecrolimus cream twice
daily to a target lesion on one side of the body and also applied a topical medical device
cream three times daily on a symmetrical target lesion on the opposite side of the body for
four weeks. After the 4-week study period, 15 of 20 (75%) sites of both treatments were rated
"clear" (0) or "almost clear" (1) by the Physician Global Assessment (PGA). Overall, there
was no statistically significant difference in PGA scores between the treatment sites
throughout the study (p=0.8236). The authors concluded: "A lipid-rich, non-steroidal, topical
medical device cream was as effective in improving the AD symptoms as pimecrolimus
cream."
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Prescription moisturizers versus OTC moisturizers
All of the above-cited studies demonstrated that each tested product is safe and effective in
treating AD, either as monotherapy or as adjuvant treatment together with other treatments.
Some of them compared the product to steroids, some to a topical immunomodulator, and
others to vehicle alone. Even if they achieve the highest marks for objectivity, quality, and
clinical value, it is impossible for them to claim that any of the prescription device
moisturizers are superior to ordinary OTC moisturizers, because none of them compared the
tested product to an ordinary non-prescription OTC emollient/moisturizer, which is
inarguably much less expensive.
There are, however, at least 2 other studies that did compare prescription moisturizers with
OTC emollients. One of them 16 compared a prescription moisturizer (Mimyx®) to a mineral
oil, petrolatum, and paraffin OTC moisturizer that had been commercially available for over
100 years. This investigator-blinded research utilized a split-body model in 60 subjects (30
with mild eczema, 30 with moderate eczema) to examine effect of the two products in the
treatment of eczema of the arms or legs. The subjects with mild eczema were asked to use the
OTC moisturizer twice daily to the randomized right or left target limb and a prescription
device to the other randomized target limb. In addition, 30 subjects with moderate eczema
were asked to use the OTC moisturizer and 0.1% triamcinolone acetonide cream (TAC) twice
daily to the randomized limb and a prescription device and TAC. All subjects with mild and
moderate eczema were rated as being clear by the dermatologist investigator at the end of the
study. Each target site limb was evaluated separately, and at no time point during the study
(i.e., at week 1, 2, or 4) were there any statistically significant differences between the OTC
and device moisturizer. The subject assessments also showed no statistically significant
differences between the OTC and device moisturizer at any time point. The investigator
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concluded that parity was established in the treatment of mild-to-moderate eczema with both
products that showed excellent results.
The other study that we found 17 compared the clinical efficacy of two prescription
moisturizers and one petrolatum-based skin protectant moisturizer that had been on the
market for many years as an OTC product (OTC-Pet). Thirty-nine patients aged 2-17 years
with mild-to-moderate AD were randomized 1:1:1 to receive one of three treatments with
instructions to apply the treatment, three times daily for three weeks. Evaluations were
carried out at baseline, day 7, and day 21, and the following were measured: IGA (0-4), body
surface area (BSA) involvement (0-100), investigator's global assessment of improvement
(IGAI, 0-6), eczema area and severity index (EASI, 0-72), and a 100 mm visual analog scale
(VAS) for itch intensity. The final results showed no significant difference for any of the
measured parameters between the three groups on day 21. OTC-Pet demonstrated no
significant difference in clinical efficacy from prescription devices moisturizers. The
demonstration that the clinical success of OTC-Pet is at least as good as the clinical success
of prescription device moisturizers suggests that the clinical trial results presented by the
manufacturers of one agent need to be interpreted as representing the performance of that
single agent in isolation and not as testimony to its superiority over any other prescription
agents or OTC products.
What should we recommend to our patients?
If there is any scientific, evidence-based support for the superiority of the prescription device
moisturizers over well-crafted, traditional, petrolatum-based OTC emollients, we could not
find it. The obvious $64,000 question would be, what should we recommend to our patients?
It seems that this pressing question will have to remain unanswered until more convincing
evidence-based and unbiased information becomes available.
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Moisturizers for AD: Facts and controversies
 There is now scientific evidence of genetically driven skin barrier anomalies in atopic
patients.
 These barrier anomalies facilitate sustained antigen ingress through the defective
barrier which can bring about a Th2-dominant response. It enhances the
transepidermal water loss, resulting in dry skin and leading to the release of preformed pro-inflammatory cytokines and to a cascade of events ending up in
inflammation.
 There is scientific evidence indicating that skin barrier dysfunction plays a prominent
role in the development and perpetuation of AD, the “outside-to-inside” view of AD
pathogenesis.
 Moisturizers have a pivotal role in improving and maintaining the skin barrier
function and reducing skin susceptibility to irritants 18.
 Emollients are a standard of care, the mainstay of AD therapy, and useful for both
prevention and maintenance therapy 18.
 Regular use of emollients has a short- and long-term steroid-sparing effect in mild-tomoderate AD.
 Emollients should be recommended in adequate amounts and used liberally and
frequently in atopic patients.
 The type of emollient best suited for this approach has not yet been delineated.

14

 “Barrier-repair therapeutics” has recently entered the market as prescription 510kcleared moisturizers.
 Although this new class of moisturizers has shown excellent performance,
emphasizing efficacy and safety, there is no evidence to support their superiority over
a well-crafted traditional, petrolatum-based OTC emollient.
 There is currently no definition for “barrier-repair products.” It is unclear, if
presently available products justify such a category. The issue is even more cloudy
with the term “moisturizer,” used for products which do not moisturize. This term was
actually invented by Madison Avenue marketeers for promoting the simplistic idea
that moistening the skin will keep it soft and flexible; however, there is currently no
medical definition of these so called moisturizers or emollients.
 The approval of emollients , which do not contain demonstrably active ingredients
different from “ordinary” emolients , as prescription devices seems to be a
technicality that confuses the issue.
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